Barclays analyst Carter Gould lowered the firm’s price target on Vor Bio to $3 from $10 and keeps an Overweight rating on the shares. The analyst updated models in the small cap biopharma space following the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: